Skip to main content

NARG1 Antibody

Novus Biologicals, part of Bio-Techne | Catalog # NBP1-21387

Novus Biologicals, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
NBP1-21387

Key Product Details

Species Reactivity

Validated:

Human, Mouse

Predicted:

Orangutan (100%). Backed by our 100% Guarantee.

Applications

Immunocytochemistry/ Immunofluorescence, Immunohistochemistry, Immunohistochemistry-Paraffin, Immunoprecipitation, Western Blot

Label

Unconjugated

Antibody Source

Polyclonal Rabbit IgG

Concentration

0.2 mg/ml

Product Summary for NARG1 Antibody

Immunogen

The immunogen recognized by this antibody maps to a region between residue 816 and 866 of human NMDA receptor regulated 1 using the numbering given in entry NP_476516.1 (GeneID 80155).

Clonality

Polyclonal

Host

Rabbit

Isotype

IgG

Scientific Data Images for NARG1 Antibody

Western Blot: NARG1 Antibody [NBP1-21387]

Western Blot: NARG1 Antibody [NBP1-21387]

Western Blot: NARG1 Antibody [NBP1-21387] - Whole cell lysate from HeLa (5, 15 and 50 mcg for WB; 1 mg for IP, 20% of IP loaded), 293T (T; 50 mcg) and mouse NIH3T3 (M; 50mcg) cells. NBP1-21387 used for WB at 0.04 mcg/ml (A) and 1 mcg/ml (B) and used for IP at 3 mcg/mg lysate.
Immunocytochemistry/ Immunofluorescence: NARG1 Antibody [NBP1-21387]

Immunocytochemistry/ Immunofluorescence: NARG1 Antibody [NBP1-21387]

Immunocytochemistry/Immunofluorescence: NARG1 Antibody [NBP1-21387] - Human colon carcinoma
Immunohistochemistry-Paraffin: NARG1 Antibody [NBP1-21387]

Immunohistochemistry-Paraffin: NARG1 Antibody [NBP1-21387]

Immunohistochemistry-Paraffin: NARG1 Antibody [NBP1-21387] - Colon carcinoma used at a dilution of 1:80.

Applications for NARG1 Antibody

Application
Recommended Usage

Immunocytochemistry/ Immunofluorescence

1:50 to 1:250

Immunohistochemistry

1:100-1:500

Immunohistochemistry-Paraffin

1:100-1:500

Immunoprecipitation

2-5 ug/mg lysate

Western Blot

1:2000-1:10000
Application Notes
Epitope retrieval with citrate buffer pH 6.0 is recommended for FFPE tissue sections.
Please Note: Optimal dilutions of this antibody should be experimentally determined.

Formulation, Preparation, and Storage

Purification

Immunogen affinity purified

Formulation

TBS and 0.1% BSA

Preservative

0.09% Sodium Azide

Concentration

0.2 mg/ml

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C. Do not freeze.

Background: NARG1

NARG1 (NMDA receptor-regulated 1) is also known as NATH (N-acetyltransferase). The NARG1 gene, along with NARG2 and NARG3, was originally identified as a gene regulated by NMDA receptors in developing neurons. The NARG1 gene was found to be a homolog of a yeast N-terminal acetyltransferase that functions in control of the G(0) phase of the cell cycle. NARG1 was also identified as NATH in experiments set out to identify genes differentially expressed in papillary thyroid carcinoma (PTC). The NATH protein has been shown to form a complex with human ARD1 where they function as an acetyltransferase and interact with ribosomal subunits. The ARD1/NATH complex plays an important role in cell survival. Alternative names for NARG1 include protein tubedown-1, Tbdn100, gastric cancer antigen Ga19, and GA19.

Alternate Names

FLJ13340, GA19, Gastric cancer antigen Ga19, N(alpha)-acetyltransferase 15, NatA auxiliary subunit, NARG1, NATHGa19, NMDA receptor-regulated protein 1, N-terminal acetyltransferase, Protein tubedown-1, Tbdn100, TBDN100NatA auxiliary subunit, transcriptional coactivator tubedown-100, tubedown-1

Entrez Gene IDs

80155 (Human)

Gene Symbol

NAA15

Additional NARG1 Products

Product Documents for NARG1 Antibody

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Product Specific Notices for NARG1 Antibody

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Loading...
Loading...
Loading...
Loading...